THIS PRESS RELEASE MAY NOT BE DISCLOSED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR TO AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SWITZERLAND, SINGAPORE, USA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN PROSTATYPE GENOMICS AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.
Prostatype Genomics AB ("Prostatype Genomics" or the "Company") announces that the Company's board, with the support of the authorization from the extraordinary general meeting on 21 April 2023, has resolved to issue 588,000 shares as guarantee compensation directed to a number of the guarantors who provided guarantee commitments in the preferential share issue that the Company carried out during the period 27 April to 11 May 2023, in accordance with the guarantee agreements entered into.
The guarantors who provided guarantee commitments in the preferential share issue had the option of having the compensation paid out in cash or in the form of issued shares in the Company, which was previously communicated in connection with the preferential share issue. In total, three guarantors have chosen to have the guarantee compensation paid out in shares. The company's board has therefore resolved, with the support of the authorization from the extraordinary general meeting on 21 April 2023, to issue 588,000 shares as compensation to these guarantors, which will increase the company's share capital by approximately SEK 35,280. The reasons for the deviation from the shareholders' preferential right were to enable a successful capital acquisition and to fulfill the guarantee agreements entered into.
The shares are issued at a price of SEK 0.25 per share, which corresponds to the subscription price in the preferential share issue and is therefore considered market-based in the board's assessment. The board has resolved that payment shall be made by offsetting the respective guarantor's claim on the Company. The guarantors’ total claim amounts to SEK 147,000. When these 588,000 shares together with the 96,009,888 shares that were issued in the preferential share issue have been registered with the Swedish Companies Registration Office, the number of shares in the Company will amount to 119,460,007 shares, and the Company's share capital to approximately SEK 7,167,600.42. The dilution that accrues as a result of the directed share issue to the guarantors amounts to approximately 0.5 percent after the preferential share issue has been registered.
The company has had no specific costs related to the directed share issue as this takes place as part of the work on the preferential share issue. However, the cash part of the warranty compensation that the Company needs to pay out is reduced to approximately SEK 2.0 million, from previously SEK 2.1 million.
Prostatype Genomics has appointed Erik Penser Bank AB and Lindahl law firm as financial and legal advisors respectively, in connection to the preferential share issue.
For further information regarding Prostatype Genomics, please contact:
Nicklas Rosendal, Press Contact
Telephone: +46 708-89 33 34
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
Svensk Kapitalmarknadsgranskning AB
The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Prostatype Genomics. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics takes place solely through the prospectus that Prostatype Genomics published on 24 April 2023.
The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hongkong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.